Short Interest in Tema Oncology ETF (NASDAQ:CANC) Decreases By 37.5%

Tema Oncology ETF (NASDAQ:CANC) saw a significant decline in short interest during the month of October. As of October 31st, there was short interest totalling 1,000 shares, a decline of 37.5% from the October 15th total of 1,600 shares. Based on an average trading volume of 3,200 shares, the days-to-cover ratio is currently 0.3 days.

Institutional Trading of Tema Oncology ETF

A hedge fund recently raised its stake in Tema Oncology ETF stock. Thrivent Financial for Lutherans raised its holdings in Tema Oncology ETF (NASDAQ:CANC) by 25.1% during the 3rd quarter, according to its most recent filing with the Securities and Exchange Commission. The fund owned 399,509 shares of the company’s stock after buying an additional 80,133 shares during the period. Thrivent Financial for Lutherans owned 22.96% of Tema Oncology ETF worth $11,351,000 at the end of the most recent reporting period.

Tema Oncology ETF Stock Down 0.8 %

CANC stock traded down $0.22 during midday trading on Thursday, reaching $27.64. The stock had a trading volume of 380 shares, compared to its average volume of 6,734. Tema Oncology ETF has a twelve month low of $22.57 and a twelve month high of $30.11. The business has a fifty day simple moving average of $28.37 and a two-hundred day simple moving average of $28.14. The firm has a market cap of $48.09 million, a price-to-earnings ratio of 26.86 and a beta of 1.11.

Tema Oncology ETF Company Profile

The Tema Oncology ETF (CANC) is an exchange-traded fund that mostly invests in health care equity. The fund is actively managed, investing in stocks of companies focused on cancer treatment and management from issuers all around the world. The fund uses a bottom-up approach to select pioneering companies at perceived attractive valuations CANC was launched on Aug 15, 2023 and is issued by Tema.